KRAS

[Nature Reviews Cancer] The authors review convergent and disparate metabolic networks regulated by oncogenic mutant KRAS in colon, lung and pancreas tumors, with an emphasis on co-occurring mutations and the role of the tumor microenvironment.

[Auris Medical Holding Ltd.] Auris Medical Holding Ltd. announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform, based on outcomes from studies with OligoPhore™ enabled KRAS silencing, and a well-defined regulatory and development pathway.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers suggested that missense p53 mutations may have contributed to worse PDAC prognosis by promoting a more vigorous fibrotic tumor microenvironment and impeded the ability of the immune system to eliminate the cancer cells.

[Leukemia] The authors built mouse models expressing activated Il7r (aIL7R). B-cell intrinsic aIL7R mice developed spontaneous B-cell acute lymphoblastic leukemia, demonstrating sufficiency of Il7r activating mutations in leukemogenesis.

[Cell Reports] Researchers determined that SRC-inhibitor-mediated suppression of p130Cas phosphorylation impaired MYC transcription through a DOCK1-RAC1-β-catenin-dependent mechanism.

[Scientific Reports] Primary pancreatic epithelial cells were isolated from pancreatic ducts of domestic pigs. A transformed cell line was generated from these primary cells with oncogenic KRAS and SV40T.